Clinical outcomes with fixed-duration therapy (UK real-world data) compared with continuous lenalidomide and low-dose dexamethasone therapy (FIRST trial; MM-020) for transplant-ineligible patients with newly-diagnosed multiple myeloma.

Similarly, median PFS (Figure 1(B)) and TTNT (Figure 1(C)) were significantly shorter in the FDT cohort (9.0 vs. 25.7 months; I p i < 0.0001 and 16.7 vs. 42.2 months; I p i < 0.0001, respectively); after 5 years, more patients in the FDT cohort had progressed to second-line treatment (94% vs. 61%). Conversely, a study that evaluated patient preferences for multiple myeloma (MM) treatment attributes reported that achieving TFI after frontline therapy can sometimes drive patient preference for FDT [[11]]. The median frontline treatment duration of 4.6 months for patients in our real-world FDT cohort was substantially shorter than the 15.4 months for patients treated with MPT in the MM-020 trial [[3]]. [Extracted from the article]